Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain

Salina Akter, Hiroyuki Sasaki, Kazi Rasel Uddin, Yuko Ikeda, Hiroki Miyakawa, Shigenobu Shibata

Research output: Contribution to journalArticle

Abstract

Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

Original languageEnglish
Pages (from-to)119-128
Number of pages10
JournalLife Sciences
Volume216
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Anti-Anxiety Agents
Brain
Corticosterone
Amygdala
Body Weight
Inbred ICR Mouse
Hydroxyindoleacetic Acid
Caseins
Anxiety Disorders
Serum
Cerebral Cortex
Weight Gain
Neurotransmitter Agents
Hippocampus
Anxiety
Diet
Light
Pharmaceutical Preparations
Nutrition
Metabolites

Keywords

  • Amygdala
  • Anxiety
  • Monoamines
  • γ-oryzanol

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain. / Akter, Salina; Sasaki, Hiroyuki; Uddin, Kazi Rasel; Ikeda, Yuko; Miyakawa, Hiroki; Shibata, Shigenobu.

In: Life Sciences, Vol. 216, 01.01.2019, p. 119-128.

Research output: Contribution to journalArticle

Akter, Salina ; Sasaki, Hiroyuki ; Uddin, Kazi Rasel ; Ikeda, Yuko ; Miyakawa, Hiroki ; Shibata, Shigenobu. / Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain. In: Life Sciences. 2019 ; Vol. 216. pp. 119-128.
@article{0e5abc781d0d4fbdabcf7960f4f9226c,
title = "Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain",
abstract = "Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5{\%} in the mouse standard diet (14{\%} casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5{\%} GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5{\%} GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5{\%} GORZ treatment. Moreover, 0.5{\%} GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5{\%} GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.",
keywords = "Amygdala, Anxiety, Monoamines, γ-oryzanol",
author = "Salina Akter and Hiroyuki Sasaki and Uddin, {Kazi Rasel} and Yuko Ikeda and Hiroki Miyakawa and Shigenobu Shibata",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.lfs.2018.11.042",
language = "English",
volume = "216",
pages = "119--128",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Anxiolytic effects of γ-oryzanol in chronically- stressed mice are related to monoamine levels in the brain

AU - Akter, Salina

AU - Sasaki, Hiroyuki

AU - Uddin, Kazi Rasel

AU - Ikeda, Yuko

AU - Miyakawa, Hiroki

AU - Shibata, Shigenobu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

AB - Aims: The present study was aimed to investigate the anxiolytic effect of γ-oryzanol (GORZ) during chronic restraint stress treatment (CRST), which is a well-documented model of stress-related disorders, like anxiety, and its potential molecular mechanisms. Materials and methods: In this experiment, 5-week-old male ICR mice were used and the concentration of GORZ was fixed at 0.5% in the mouse standard diet (14% casein, AIN 93 M). Mice were immobilized daily for 3 h from ZT 2.5 to 5.5 (ZT0 was designated as light-on time) for 20 consecutive days, followed by behavioral testing, including the open field test (OFT) and elevated plus maze (EPM) test. The concentration of serum corticosterone (CORT) was measured. In addition, the expression of central monoamine neurotransmitters with their metabolites in the hippocampus, cerebral cortex, and amygdala of the brain were examined. Key findings: 0.5% GORZ partially blocked stress-induced reduction of body weight gain while stressed mice had significantly lower body weights during the entire experimental period. Further, 0.5% GORZ treatment could significantly improve the main behavioral parameters even in CRST situations. The significant increase in serum CORT levels indicated CRST-induced stress, which was almost unaffected by 0.5% GORZ treatment. Moreover, 0.5% GORZ also supported the anxiolytic mechanism with enhancement of 5-HIAA and NE levels in the amygdala of brain after CRST. Significance: Taken together, our studies suggested that 0.5% GORZ is a potential therapeutic drug candidate against anxiety under chronic stress conditions.

KW - Amygdala

KW - Anxiety

KW - Monoamines

KW - γ-oryzanol

UR - http://www.scopus.com/inward/record.url?scp=85056807560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056807560&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2018.11.042

DO - 10.1016/j.lfs.2018.11.042

M3 - Article

VL - 216

SP - 119

EP - 128

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -